AU2010322114B2 - Methods and compositions for treating solid tumors and other malignancies - Google Patents

Methods and compositions for treating solid tumors and other malignancies Download PDF

Info

Publication number
AU2010322114B2
AU2010322114B2 AU2010322114A AU2010322114A AU2010322114B2 AU 2010322114 B2 AU2010322114 B2 AU 2010322114B2 AU 2010322114 A AU2010322114 A AU 2010322114A AU 2010322114 A AU2010322114 A AU 2010322114A AU 2010322114 B2 AU2010322114 B2 AU 2010322114B2
Authority
AU
Australia
Prior art keywords
methyl
biphenyl
amide
carboxylic acid
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010322114A
Other languages
English (en)
Other versions
AU2010322114A1 (en
Inventor
Silvia Buonamici
Marion Dorsch
Carlos Garcia-Echeverria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43384585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010322114(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2010322114A1 publication Critical patent/AU2010322114A1/en
Application granted granted Critical
Publication of AU2010322114B2 publication Critical patent/AU2010322114B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010322114A 2009-11-18 2010-11-17 Methods and compositions for treating solid tumors and other malignancies Ceased AU2010322114B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26234209P 2009-11-18 2009-11-18
US61/262,342 2009-11-18
US29203210P 2010-01-04 2010-01-04
US61/292,032 2010-01-04
PCT/US2010/056942 WO2011062939A1 (en) 2009-11-18 2010-11-17 Methods and compositions for treating solid tumors and other malignancies

Publications (2)

Publication Number Publication Date
AU2010322114A1 AU2010322114A1 (en) 2012-05-31
AU2010322114B2 true AU2010322114B2 (en) 2014-07-31

Family

ID=43384585

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010322114A Ceased AU2010322114B2 (en) 2009-11-18 2010-11-17 Methods and compositions for treating solid tumors and other malignancies

Country Status (18)

Country Link
US (2) US20120232087A1 (https=)
EP (1) EP2501370A1 (https=)
JP (1) JP2013511526A (https=)
KR (1) KR20120107962A (https=)
CN (2) CN102665700A (https=)
AU (1) AU2010322114B2 (https=)
BR (1) BR112012011823A2 (https=)
CA (1) CA2781210A1 (https=)
CL (1) CL2012001271A1 (https=)
IL (1) IL219636A0 (https=)
MA (1) MA33739B1 (https=)
MX (1) MX2012005695A (https=)
NZ (1) NZ599964A (https=)
PH (1) PH12012500911A1 (https=)
RU (1) RU2012125152A (https=)
TN (1) TN2012000205A1 (https=)
WO (1) WO2011062939A1 (https=)
ZA (1) ZA201203325B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627911T3 (es) 2009-11-18 2017-08-01 Plexxikon, Inc. Derivados de N-[2-fluoro-3-(4-amino-7H-pirrolo[2,3-d]pirimidin-5-carbonil)-fenil]-4-bencenosulfonamida como moduladores de la proteína quinasa Raf para el tratamiento del cáncer
SG194800A1 (en) * 2011-06-02 2013-12-30 Novartis Ag Biomarkers for hedgehog inhibitor therapy
WO2013106812A1 (en) * 2012-01-12 2013-07-18 Board Of Regents, The University Of Texas System Personalized medicine for the prediction of therapy targeting the hedgehog pathway
EP2914253B1 (en) 2012-11-05 2018-01-03 NantBioScience, Inc. Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
CN103524535B (zh) * 2013-10-16 2016-07-13 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的胺基噻唑-吡啶杂环化合物
EP3565520B1 (en) 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
DK3786160T3 (da) 2017-10-27 2022-08-22 Boehringer Ingelheim Int Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
US20210346385A1 (en) * 2018-09-21 2021-11-11 MSB Holdings, Inc Taste-masked dosage forms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131201A2 (en) * 2006-05-05 2007-11-15 Irm Llc Compounds and compositions as hedgehog pathway modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JP5161102B2 (ja) 2005-11-22 2013-03-13 クドス ファーマシューティカルズ リミテッド ｍＴＯＲ阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体
CA2659851C (en) 2006-08-23 2014-02-25 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
CA2681162C (en) * 2007-03-15 2015-11-24 Novartis Ag Benzyl and pyridine derivatives as modulators of hedgehog pathway
BR122021010386B1 (pt) * 2007-06-07 2021-08-03 Sun Pharma Global Fze Uso de n-(6-((2r,6s)-2,6-dimetilmorfolino)piridin-3-il)-2-metil-4'-(trifluorometoxi) bifenil-3- carboxamida como moduladores da rota de hedgehog
US8153633B2 (en) * 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009112266A1 (en) * 2008-03-12 2009-09-17 Ludwig-Maximilians-Universität Active substance combination with gemcitabine for the treatment of epithelial cancer
UA102250C2 (ru) * 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131201A2 (en) * 2006-05-05 2007-11-15 Irm Llc Compounds and compositions as hedgehog pathway modulators

Also Published As

Publication number Publication date
US20150025074A1 (en) 2015-01-22
NZ599964A (en) 2014-08-29
AU2010322114A1 (en) 2012-05-31
IL219636A0 (en) 2012-07-31
CL2012001271A1 (es) 2012-10-12
RU2012125152A (ru) 2013-12-27
CN104224791A (zh) 2014-12-24
BR112012011823A2 (pt) 2019-09-24
EP2501370A1 (en) 2012-09-26
PH12012500911A1 (en) 2012-11-26
CN102665700A (zh) 2012-09-12
KR20120107962A (ko) 2012-10-04
ZA201203325B (en) 2013-01-30
US20120232087A1 (en) 2012-09-13
JP2013511526A (ja) 2013-04-04
MX2012005695A (es) 2012-06-13
CA2781210A1 (en) 2011-05-26
MA33739B1 (fr) 2012-11-01
TN2012000205A1 (en) 2013-12-12
WO2011062939A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
AU2010322114B2 (en) Methods and compositions for treating solid tumors and other malignancies
TWI827646B (zh) Ptpn11抑制劑
AU2009299927B2 (en) Smoothened antagonism for the treatment of hedgehog pathway-related disorders
JP6669744B2 (ja) ブロモドメインのインヒビターとしての置換ピロロピリジン
JP6669745B2 (ja) ブロモドメインのインヒビターとしての置換ピロロピリジン
KR101217316B1 (ko) 헷지호그 경로 조절제로서의 바이페닐카르복스아미드 유도체
CN112351780A (zh) Ptpn11的取代的杂环抑制剂
JP2021528469A (ja) Ｔ細胞アクティベーターとして有用なナフチリジノン化合物
CN111386116A (zh) 一种具有pd-l1抑制活性的化合物、其制备方法及用途
MX2011000721A (es) Derivados de piridazina como inhibidores de smo.
CN116234797A (zh) 用于治疗癌症的tead的杂环抑制剂
AU2023269412A1 (en) Methods of treating myeloid malignancies using bcl-2 inhibitor
US20150209365A1 (en) Methods and Compositions for Treating Luekemia
CN116621921A (zh) 酰胺类化合物、其制备方法及其在医药上的应用
AU2014201941A1 (en) Methods and compositions for treating leukemia
HK40088635A (zh) 用於治疗癌症的tead的杂环抑制剂
HK40037519A (en) Substituted heterocyclic inhibitors of ptpn11
AU2014280951A1 (en) Biphenylcarboxamide derivatives as hedgehog pathway modulators
HK1183625A (en) Smoothened antagonism for the treatment of hedgehog pathway-related disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired